ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Mexico Pharmaceutical Firms Find They Rank No. 2 Among Manufacturers

--Mexican market seen as essential for global pharmaceutical firms --Industry accounts for 1.2% of Mexican GDP --Underutilized manufacturing capacity leaves room for export growth By Amy Guthrie MEXICO CITY--Mexican pharmaceutical companies were surprised to discover recently that they represent the country's second-biggest manufacturing sector. The sheer size of the Mexican market, with a population of more than 112 million people and around 2.5 billion unit sales of medication a year, makes the country a strategic market for multinational pharmaceutical firms such as Pfizer Corp. (PFE), Novartis AG (NVS), Merck & Co. (MRK) and Sanofi (SNY), although market share is highly fragmented. But it wasn't until industry chamber Canifarma concluded an assessment this month using data from its 186 affiliates that it realized its own heft. With projected annual sales of 195.20 billion pesos ($14 billion) for 2012, pharmaceuticals are second only to automobiles in terms of importance to Mexico's manufacturing-heavy economy. Manufacturing as a whole accounts for more than 17% of Mexico's $1 trillion annual gross domestic product; pharmaceuticals supply 7.2% of manufacturing GDP and 1.2% of overall GDP, Canifarma says. In addition, the industry attracts about $1.52 billion a year in investment, or more than 8% of the foreign direct investment the entire country receives annually. "We're more relevant than we thought," said Rogelio Ambrosi, president of Canifarma and chief executive of Merck's Mexican operations, in an interview. Merck claims just over 3% of Mexican pharmaceutical sales. The Canifarma data show that the Mexican domestic economy is also a bright spot in a troubled international economic environment. Annual sales of medicine, including for veterinary use, have grown in Mexico by more than 6% sequentially in recent years. Research firm Decision Resources calculates annual global pharmaceutical sales at just over $700 billion, with U.S. consumers accounting for almost half that amount. Rising sales in emerging markets such as Mexico are compensating for stagnating and even declining sales in developed countries. Three quarters of the medicine sold in Mexico is produced domestically, but the industry is operating at only 70% of installed manufacturing capacity. The industry group figures that Mexican manufacturers will export $1.2 billion in pharmaceuticals this year, with 65% of the export volume heading for other parts of Latin America. Some Mexican pharmaceuticals factories are recognized by foreign health authorities, such as the U.S. Food and Drug Administration, while the industry as a whole is seeking certification from the Pan American Health Organization. Such recognitions could facilitate export growth. Write to Amy Guthrie at amy.guthrie@dowjones.com.

Stock News for Novartis (NVS)
DateTimeHeadline
02/03/201611:04:00Investors' Fears Eased as Glaxo Posts Solid Results -- Update
02/03/201608:30:00GlaxoSmithKline Posts $510 Million Net Loss
02/03/201608:23:00GlaxoSmithKline Posts GBP354 Million Net Loss in 4Q
01/28/201616:40:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/27/201616:30:00Radius Health Announces Clinical Collaboration With a Leading...
01/27/201609:57:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201605:10:00Global Stocks Edge Lower Ahead of U.S. Interest Rate Decision
01/27/201604:44:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201603:01:00Novartis Net Profit Falls 57% --Update
01/27/201602:50:00Novartis Net Profit Falls 57%
01/27/201602:02:00Novartis 4Q Net Profit Falls 57% as Eye-Care Unit Drags on Results
01/22/201611:53:00CEOs Sanguine on M&A Prospects in Spite of Markets Dive --Update
01/22/201609:06:00Novartis AG 4Q 2015 -- Forecast
01/20/201619:29:00Drug and Diagnostic Companies Issue Joint Declaration on Antibiotics
01/11/201610:10:00Juno Agrees to Acquire AbVitro
12/17/201519:49:00Ligand Pharma to Buy Genetic Engineering Company OMT -- 2nd Update
12/17/201505:10:00Global Stocks Rally After Fed Decision
12/07/201515:53:00U.S. Stocks Fall as Oil Keeps Sliding
12/04/201508:00:03Why Ophthotech Corporation Shares Soared Higher Last Month
11/29/201513:40:02Insurers Don't Want to Pay for Pricey Cancer Meds

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad